The case for a ketogenic diet in the management of kidney disease

Shaminie J Athinarayanan, Caroline G P Roberts, Chandan Vangala, Greeshma K Shetty, Amy L McKenzie, Thomas Weimbs, Jeff S Volek

ABSTRACT
Ketogenic diets have been widely used for weight loss and are increasingly used in the management of type 2 diabetes. Despite evidence that ketones have multiple positive effects on kidney function, common misconceptions about ketogenic diets, such as high protein content and acid load, have prevented their widespread use in individuals with impaired kidney function. Clinical trial evidence focusing on major adverse kidney events is sparse. The aim of this review is to explore the effects of a ketogenic diet, with an emphasis on the pleiotropic actions of ketones, on kidney health. Given the minimal concerns in relation to the potential renoprotective effects of a ketogenic diet, future studies should evaluate the safety and efficacy of ketogenic interventions in kidney disease.

INTRODUCTION
Low carbohydrate eating patterns including a very low carbohydrate or ketogenic diet have been successfully used for weight loss and remitting type 2 diabetes (T2D). Among patients with T2D, the prevalence of chronic kidney disease (CKD), whether characterized as a reduced estimated glomerular filtration rate (eGFR) function or albuminuria is almost 40%. Yet, a ketogenic diet is cautioned against in individuals with impaired kidney function, in part, due to concerns about increased protein intake. The effect of protein intake in CKD is controversial, but high protein intake has been associated with hyperfiltration, increased acid excretion, and, potentially, a decline in kidney function. However, protein intake on a well-formulated ketogenic diet (WFKD) is moderate to effectively permit nutritional ketosis. Dietary analysis of very low carbohydrate studies usually reports daily protein intake ranging from 0.6 g/kg to 1.4 g/kg, which is similar to that in the standard American diet and below the high protein threshold (≥2.0 g/kg) believed to be of concern. The Kidney Disease Outcomes Quality Initiative clinical practice guideline for nutrition in CKD not dependent on dialysis recommends a “low-protein diet providing 0.55–0.6 g of dietary protein/kg body weight/day, or a very low-protein diet providing 0.28–0.43 g of dietary protein/kg of body weight/day with additional keto acid/amino acid analogs to meet protein requirements (0.55–0.60 g/kg/day). In contrast, the Kidney Disease Improving Global Outcomes (KDIGO) 2022 CKD guideline recommended a slightly higher daily protein allowance of 0.8 g/kg/day for individuals with advanced CKD with or without T2D. The Modification of Diet in Renal Disease (MDRD) study, a landmark trial examining the effect of protein restriction among 585 patients with non-diabetic CKD, did not demonstrate a significantly slower progression of disease, and in fact a very low protein diet (0.28 g/kg/day) was associated with increased risk of death at a median follow-up of 3.2 years. Null findings from MDRD are one of numerous inconsistent results studying protein restriction in patients with CKD. Taken altogether, systematic reviews have suggested—at best—a modest benefit for patients on a low protein diet and given the aforementioned long-term data noting increased risk of death with very low protein diets, most nephrology experts are more comfortable with moderate protein restriction to the degree of 0.8 g/kg/day as recommended by the KDIGO 2022 guideline.

The impact of carbohydrate restriction interventions on kidney function is poorly understood. Existing studies consistently reported improvements in glycemic control, blood pressure, weight, and insulin resistance, all of which have favorable downstream implications for slowing kidney disease progression. In addition, ketone bodies themselves have a myriad of physiologic and signaling effects that could elicit renoprotective effects. For example, the renoprotective effect of sodium-glucose cotransporter 2 inhibitors (SGLT2i) has been postulated to be partially mediated by the modest medication-induced ketosis. This low-grade ketosis induced by SGLT2i may directly or indirectly benefit the kidney by serving as an energy source.
source during stress and kidney injury, and through its anti-inflammatory, antifibrotic, and antioxidant effects (figure 1). Given that SGLT2-induced ketosis may be beneficial for the kidney, endogenously produced ketones resulting from a WFKD may prove to be another therapeutic option for diabetic nephropathy or kidney disease.

In this review, we explore the pleiotropic roles and signaling effects of ketones on kidney physiology, address potential concerns of ketogenic therapy, summarize the available literature on the effect of low carbohydrate diets on kidney function, and discuss future studies that could help address the gaps in knowledge and discrepancies in the literature.

**Potential roles of ketones on kidney pathophysiology and disease**

**Ketones as an alternative energy-efficient fuel**

The human body naturally produces ketones, mostly in the liver, at varying rates that result in circulating ketones that span more than four orders of magnitude (<0.01 to >10 mM) depending primarily on a person’s carbohydrate intake and insulin level. Increased lipolysis and ketogenesis are upregulated in response to a low insulin-to-glucagon ratio, which occurs during calorie restriction/fasting, prolonged exercise, consumption of a ketogenic diet, or pathologic insulin deficiency. In the liver, when production of fatty acyl coenzyme A (CoA) increases during low insulin secretion and increased lipolysis, fatty acyl CoA is transported to the mitochondrial matrix, where it is then β-oxidized to produce acetyl-CoA. Acetyl-CoA is either converted to malonyl CoA or to acetoacetyl CoA (figure 2). Acetoacetyl CoA and acetyl-CoA are further condensed by a rate-limiting enzyme, 3-hydroxy 3-methylglutaryl-CoA synthase 2 (HMGS2) to generate hydroxymethylglutaryl CoA (HMG-CoA). HMG-CoA is then converted into acetoacetate (AcAc) by hydroxymethylglutaryl coenzyme A lyase (HMGL). Finally, AcAc is reduced to β-hydroxybutyrate (BHB) by BHB dehydrogenase (BDH) (figure 2). Both AcAc and BHB are released from the liver and transported in the blood circulation to extrahepatic tissues where they can have signaling effects and be metabolized and released or oxidized to produce energy. BHB is a vital energy source for the brain with uptake occurring in proportion to circulating levels. As such, during prolonged starvation, ketones can provide over half the brain’s energy requirements. Generally, glucose is considered the most efficient fuel since it produces more energy per mole of oxygen than ketones, but ketones are less likely to cause lactic acidosis.

**Figure 1** Summary of pleiotropic renal protective effect of ketones and carbohydrate restriction. BHB, β-hydroxybutyrate; mTORC1, mammalian target of rapamycin complex 1; NLRP3, NOD-, LRR-, and pyrin domain-containing 3; PGC-1α, peroxisome proliferator-activator receptor γ (PPARγ) coactivator-1-alpha; FFAR-3, free fatty acid receptor-3; HCAR, hydroxycarboxylic acid receptor-2; HDAC-3, Histone deacetylase-3; NRF2, nuclear factor erythroid 2-related factor 2; SIRT1, silent information regulator transcript-1.
Clinical care/Education/Nutrition

ATP per oxygen consumed with a phosphate/oxygen (P/O) ratio of 2.5. However, in a state of insulin resistance where glucose uptake and oxidation are impaired, BHB is an effective alternative dense energy molecule with a P/O ratio of 2.50. In contrast to free fatty acids (FFAs), another form of energy-dense fuel, BHB gives better ATP yield per oxygen consumed, is water soluble, and generates fewer reactive oxygen species (ROS).

The kidney is among the most metabolically active organs, with very high oxygen demand and the second-highest mitochondrial density after the myocardium. While oxidative metabolism is the principal source of energy in the kidney, the fuel substrates for metabolism differ across regions of the kidney. In the healthy kidney, both fatty acid oxidation (FAO) in the proximal tubules and glycolysis in the distal tubules support its metabolism. The renal cortex, especially the S1/S2 tubule segments, generates energy primarily from FFAs, lactate, and glutamate versus glucose. The outer medulla uses glucose, lactate, FFAs, and ketones for energy. However, in diseased kidneys, mitochondrial dysfunction has been reported as a key pathologic feature that contributes to disease initiation and progression. For example, in diabetic nephropathy (DN), hyperglycemia-induced flux of glycolysis increases oxygen demand with the by-product of amplified ROS. Excess glucose use in the kidney shifts the energy reliance from fatty acid metabolism to glycolysis, even in the proximal tubules.

The renoprotective effect of SGLT2i in diabetic kidney disease is driven by amelioration of the pathologic metabolic shift from FAO to glycolysis. SGLT2i decreases reabsorption of excessive glucose, reduces energy production from glucose in the kidney, and increases fatty acid utilization in the kidney. Furthermore, the glycosuric effect of SGLT2i also augments the BHB level in the kidney mainly through increased production of ketones rather than reduced kidney clearance. The kidney is indeed an avid consumer of ketones. BHB serves as an important alternative source of energy for the kidney during metabolic imbalance. It can be effectively metabolized in all nephron regions, except the S1/S2 proximal tubule segments. During starvation or fasting, the BHB level in the kidney increases 20-fold and is used as a substrate for mitochondrial energy production. In the diabetic kidney disease mouse model, both SGLT2i and exogenous ketone treatment normalized the renal ATP levels by restoring its production and this intervention was also associated with kidney function improvement.

Anti-inflammatory effect
Inflammation is critical in both acute kidney disease and CKD, especially through activation of inflammasomes such as NOD-, LRR-, and pyrin domain-containing 3 (NLRP3). Numerous studies highlight the link between DN and NLRP3 inflammasome activation, which negatively impacts podocyte function, escalates the expression of inflammatory markers like IL-1β, and is also linked with albuminuria and tubulointerstitial injury. Consequently, targeting NLRP3 inflammasome inhibition emerges as a promising approach for kidney disease.
treatment, despite concerns over the safety of current experimental drugs. BHB stands out for its wide-ranging anti-inflammatory actions, including its effect on inhibiting NLRP3 inflammasome activation. BHB successfully suppresses NLRP3 inflammasome activation in human monocytes and murine neutrophils in vitro and in animal models of NLRP3-mediated diseases. Likewise, the anti-inflammatory effect of SGLT2i in diabetic rats, characterized by subdued NLRP3 inflammasome activation and lower interleukin (IL)-1β and tumor necrosis factor (TNF)-α levels, correlates with elevated BHB and reduced insulin levels in the bloodstream. BHB’s primary receptor is GPR109A (HCAR2), a G protein-coupled receptor (GPCR) that acts by suppressing cyclic adenosine monophosphate (cAMP). Beyond NLRP3 inflammasome suppression, animal studies reveal BHB diminishes other proinflammatory cytokines, including IL-6, chemokine (C–C motif) ligand 2, and monocyte chemoattractant protein-1, through activation of GPR109A, partially influenced by BHB’s effect on nuclear factor kappa B (NF-κB) translocation. In humans, ketogenic diets consistently reduce inflammation indicators. Individuals with T2D on a ketogenic diet show decreased serum C reactive protein and white cell counts, along with significant reductions in 15 out of 16 inflammatory/immune modulators after 1 and 2 years. This anti-inflammatory benefit aligns with prior findings that observed a greater reduction in 7 out of 14 inflammation/immune modulators with a ketogenic diet compared with a low-fat diet after 12 weeks.

Antifibrotic effects
The antifibrotic effect of BHB is mainly mediated through the mammalian target of rapamycin complex 1 (mTORC1) pathway. In diabetic kidney disease, mTORC1 hyperactivation is associated with kidney dysfunction and increased fibrosis. In a mouse model of non-proteinuric diabetic kidney disease, SGLT2i, particularly empagliflozin conferred renal protection by increasing endogenous ketones and suppressing mTORC1 activation in the kidneys. The treatment with empagliflozin mirrored the effect of exogenous ketone supplementation, where both treatments reduced kidney damage as evident through lower plasma cystatin-C levels and decreased interstitial fibrosis. The renoprotective mechanism of SGLT2i hinges on the ketogenesis rate-limiting enzyme HMGC2S2 highlighting ketone production’s central role in its antifibrotic effects.

Antioxidative effects
Ketones, specifically BHB, act as an important signaling molecule influencing gene expression through various regulatory pathways. BHB notably inhibits class I histone deacetylase enzyme activity in kidney tissue, enhancing the expression of genes that respond to oxidative stress, including Foxo3a and Mt2. This confers protection against oxidative stress in human kidney cells and various animal models. Studies also show that a ketogenic diet or BHB treatment can activate the major detoxification and oxidative stress nuclear factor erythroid 2-related factor 2 (Nrf2) pathway. In a spontaneous mouse model of T2D (db/db mice) treated with dapagliflozin, there was a noticeable reduction in the expression of genes related to oxidative stress compared with those treated with a standard vehicle or glimepiride. This reduction is associated with increased levels of BHB and Nrf2 protein expression. Similarly, BHB treatment in human proximal tubular cells (HK-2) led to increased Nrf2 expression and induced Nrf2 nuclear translocation. Furthermore, a ketogenic diet has been reported to increase the expression of other antioxidants such as NAD(P)H dehydrogenase quinone I (NQO1) and superoxide dismutase (SOD1/2), and ameliorated paraquat (PQ)-induced elevated lipid peroxidation, toxicity, reduced antioxidant activity and decreased Nrf2 expression, highlighting its potential therapeutic role in combating oxidative stress and tissue hypoxia.

Mitochondrial dysfunction
Mitochondrial dysfunction is another key feature of both acute kidney failure and CKD. Ketogenic diet activates the expression of peroxisome proliferator-activator receptor γ (PPARγ) coactivator-1-alpha (PGC-1α) and silent information regulator transcript-1 (SIRT1). PGC-1α is the main transcription factor that controls the expression of genes involved in mitochondrial biogenesis and function, while SIRT1 activation protects organellar damage including the mitochondria and reduces oxidative stress. In a recent study on diabetic mice, a ketogenic diet improved mitochondrial function and capacity through its activation of PGC-1α and SIRT1. Further, administration of exogenous BHB was found to increase PGC-1α and mitochondrial copy number in rat kidneys. Human data on mitochondrial function are lacking, but we obtained skeletal muscle biopsies from physically active adults before and after a 12-week ketogenic diet and demonstrated that mitochondrial function and efficiency shifted towards fat oxidation while improving insulin sensitivity.

Traditional concerns of a ketogenic diet on kidney function
Common misconceptions about ketogenic diets related to kidney health include potential adverse effects on acid–base and electrolyte balance and risk for kidney stones. The next section briefly discusses the typical renal metabolic response to a ketogenic diet that maintains pH and electrolyte status. Most work in this space has been done in the context of normal kidney function, so we mention how the situation in CKD may differ.

Electrolyte and acid–base imbalance
Ketogenic diets promote a natriuretic and diuretic effect similar to that demonstrated during starvation. This in part accounts for the typical rapid weight loss that occurs during the initiation of a ketogenic diet. If sodium intake is not commensurate with the additional loss of sodium,
two deleterious outcomes are more likely to manifest: (1) Individuals may develop common signs and symptoms of hypovolemia, colloquially referred to as “Keto-Flu,” which include dizziness when standing, lethargy, and muscle spasms/cramps. (2) Counter-regulatory mechanisms are activated that include sympathetic and aldosterone stimulation that act to preserve plasma volume by increasing sodium reabsorption and a concomitant excretion of potassium and magnesium. These side effects can be eliminated with attention to proper electrolyte intake. For most individuals with normal kidney function consuming a ketogenic diet, it should be emphasized to ingest an additional 1–2 g sodium/day (4–5 g sodium/day total), a maintenance of 3–4 g/day potassium, and sufficient fluid intake.

In CKD, a decrease in viable nephrons and reduction in glomerular filtration rate (GFR) change the kidney’s normal physiology and sodium balance. Even though an adaptive fractional increase in sodium excretion per individual nephron unit compensates for the reduced number of working nephrons, the kidney’s inability to excrete sufficient amounts of sodium results in sodium retention, extracellular fluid expansion, and blood pressure increase. Likewise, the renin–angiotensin–aldo-sterone system is activated in CKD, further exacerbating sodium retention and causing vasoconstriction which could significantly raise blood pressure. Sodium retention and its association with blood pressure in CKD are often referred to as “sodium-sensitive hypertension.” Therefore, reducing salt intake is recommended to manage hypertension in patients with CKD. The natriuretic and diuretic effect of the ketogenic diet may help alleviate sodium retention and improve systemic and glomerular blood pressure. Low carbohydrate and ketogenic diet studies often report a reduction in systolic and diastolic blood pressure and blood pressure medication requirements. However, the current recommendation of sodium intake in a WFKD is based on individuals with normal kidney function. Recommendations for sodium and electrolyte intake for patients with CKD following a ketogenic diet should be individualized by a healthcare professional based on the patient’s renal function and electrolyte status. Future studies should assess the relationship between ketosis, sodium balance, and blood pressure.

Another misconception associated with ketogenic diets relates to promotion of acidosis owing to specific food items and the weakly acidifying effects of ketones, which could worsen kidney function, bone health, and kidney disease-associated endocrinopathies. In healthy subjects provided a carefully prepared ketogenic diet with mean BHB levels >2 mM, serum bicarbonate was modestly reduced but well within normal ranges. A ketogenic diet with mild ketosis (~1 mM) in individuals with normal kidney function has no significant impact on blood pH, serum bicarbonate level, and anion gap over 21 days and 4 months. When faced with an increased acid load, normal kidney function affords compensatory increases in ammonium excretion. In a somewhat mirrored perspective where the acid load is stable and the kidney function is reduced, the fewer working nephrons compensate with increased ammoniagenesis and excretion. This adaptation results in high intrarenal ammonia, which is thought to activate the alternative complement pathway eventually leading to tubulointerstitial fibrosis. Decreases in GFR to levels below 40–50 mL/min diminish the kidney’s ability to excrete more ammonium and overall acid; hence, metabolic acidosis is more commonly encountered at this level of disease. In patients with kidney disease, clinicians commonly monitor steady-state serum bicarbonate levels to assess overall acid load. However, decreases in serum bicarbonate are often reported at a later stage of the disease and it is considered inadequate to reflect the overall acid load. Eubicarbonatemic hydrogen ion retention among patients with earlier CKD is increasingly an area of focus; thus, studying ketogenic diet in all stages of CKD requires longer term study of acid excretion and the rate of kidney function decline.

Urinary acid excretion is favored as the gold standard for estimating acid load, and the prevailing wisdom was that an increased dietary acid load would burden the kidneys further and lead to more dysfunction. However, recent observations from the rich data collected in the Chronic Renal Insufficiency Cohort Study have demonstrated pitfalls to that simplistic view. Among patients with diabetes, higher levels of net acid excretion were associated with a lower risk of CKD progression. These studies suggested that the changes in acid excretion were diet-independent and may be elicited by changes in energy metabolism and endogenous acid production from insulin resistance. Currently, the effect of ketogenic diet on net acid excretion is unknown and this would be worthwhile exploring in patients with T2D and varying stages of CKD.

Kidney stones

Kidney stones, especially genetically driven stones, are associated with an increased risk of CKD. A recent meta-analysis reported a pooled kidney stone incidence of 5.9% among patients on a ketogenic diet followed for a median of 3.7 years, compared with a historical incidence rate of <0.3% per year in the general population. Most studies reporting risk of kidney stones were in children receiving a ketogenic diet therapy for epilepsy, with higher incidence during long-term exposure (ie, 25% over 6 years, which is complicated by concurrent use of antiseizure medications (eg, carbonic anhydrase inhibitors) and other risk factors in this population. In adults with obesity, who are at higher kidney stone risk based on their higher adiposity, consuming a ketogenic diet over 2 years revealed no harmful effects on GFR, albuminuria, or fluid and electrolyte balance compared with a low-fat diet, and there was one possible, but not confirmed, case of kidney stones out of 153 subjects.
Uric acid stones are the most frequently reported by individuals on a ketogenic diet, followed by calcium oxalate stones or mixed stones with calcium and uric acid. A ketogenic diet transiently increases uric acid concentration 25%–50%, which usually peaks at 2–4 weeks, and gradually returns to prediet levels by 8 weeks. The initial rise in uric acid is concomitant with the rise in ketones, and it was postulated that the reason for this may be competition between uric acid and ketones for the same organic acid transporters, which are required for renal excretion. After several weeks, the kidney conserves ketones, presumably allowing for return of normal renal uric acid excretion and serum levels.

There may be effective strategies to mitigate the kidney stone risk in patients following a ketogenic diet. Increasing fluid intake to maintain dilute urine limits the possibility of mineral crystallization. Urine alkalinization, particularly addressing hypocitraturia, may inhibit supersaturation of calcium salts and aggregation. Moreover, studies of kidney stones have largely precluded patients with CKD where their urine parameters change alongside diminishing kidney function. A retrospective study of 811 patients with kidney stones noted that advancing kidney disease afforded reduced calcium stone formation, presumably due to reduced calcium and increased uric acid stone formation. Metabolic acidosis resulting in acidic urine pH is common among individuals with CKD. Low urine pH is a well-known risk factor for forming uric acid kidney stones due to the low solubility of uric acid in acidic conditions. At the same time, low urine pH leads to hypocitraturia which increases the risk of forming calcium oxalate kidney stones. Hence, future examination of how a ketogenic diet impacts the incidence of kidney stones among patients with T2D and CKD is paramount. Being aware of and addressing the potential kidney stone risk with well-established measures—such as urine alkalinization, correcting hypocitraturia, and increasing fluid intake—is prudent. Additionally, understanding that diet-imposed change in risk through modulation of ammonia excretion, uricosuria, calcium, citraturia, and other urinary parameters will assist with future guidance.

Current evidence on very low or low carbohydrate diet intervention and its effect on kidney function

Evidence from animal studies

Several rodent studies have specifically investigated the effects of a ketogenic diet on kidney function and disease. Two mouse studies reported benefit of ketogenic diet on DN, even reversing some of the key molecular features of DN. Poplawski et al assessed the effect of ketogenic diet on DN using both type 1 (Akita) and type 2 (db/db) murine diabetes models. In both models, the mice initially developed albuminuria on chow diet, and after transitioning to the ketogenic diet reversed and normalized urinary albumin/creatinine ratio (UACR) within 8 weeks. Furthermore, the expression of several stress-induced genes involved in oxidative stress and toxicity was completely normalized by ketogenic diet in both models, with an observed effect that was more consistently robust in the type 1 mouse model. Likewise, histopathologic features of glomerular sclerosis were also partially reversed by the ketogenic diet in the T2D mouse model. Jung et al examined db/db DN mice fed normal chow diet (dbNCD), high-fat diet (dbHFD), or ketogenic diet (dbKETO). dbKETO animals had lower UACR and blood urea nitrogen to creatinine ratio levels after 5 weeks compared with the dbNCD and dbHFD mice. Histologic analysis of the kidney showed that dbKETO mice had less fibrotic changes than the dbNCD and dbHFD mice suggesting that the dbKETO mice delayed progression of DN histologic phenotypes. Furthermore, in the same report, treatment of the human proximal tubular cell line (HK-2) with BHB led to activated autophagy by increasing the LC3 I to LC3 II ratio, phosphorylation of adenosine 5 monophosphate-activated protein kinase (AMPK), beclin, p62 degradation, NFE2 expression, and decreased glucose-induced ROS levels. Studies in a rat model of a genetic form of CKD, polycystic kidney disease, showed that a ketogenic diet not only slowed disease progression and preserved renal function in young animals but even partially reversed existing renal cystic disease in older animals. The treatment resulted in improvement of renal fibrosis and inhibition of mTORC1 and epithelial proliferation. Remarkably, the effects could be replicated by administering BHB in the drinking water in a dose-dependent manner, without any food changes. These results suggest that the actions of BHB may underlie most of the renoprotective mechanisms of nutritional ketosis, and that exogenous BHB can be effectively supplemented.

Evidence from clinical and observational studies

Clinical and observational studies that examined kidney function in response to low-carbohydrate diets ranging from <20 g/day to 30%–40% of energy expenditure are presented in online supplemental table 1. Three of the six randomized controlled trials (RCTs) reported no significant changes in kidney function in the low carbohydrate arm compared with the comparison diet group. Two of the three studies followed the participants with normal baseline eGFR for 52 weeks and the third study followed subjects with slightly lower baseline eGFR (<80) for 12 weeks. Another two RCTs reported renal benefit in the low carbohydrate arm with improvements in serum creatinine, cystatin C, eGFR, and albumin.

The study by Tirosh et al reported greater eGFR improvement in those following a low-carbohydrate diet versus both a Mediterranean and low-fat diet. The use of surrogate markers, especially serum creatinine-derived estimates of kidney function, is less accurate at higher eGFRs and may be mischaracterized amidst dietary intervention, highlighting the importance of studying major adverse kidney events and assessing cystatin C-derived kidney function estimates.
Thus far, only one RCT has reported hard kidney endpoints including all-cause mortality that compared a carbohydrate-restricted, low-iron, polyphenol enriched diet (CR-LIPE) with a standard protein restriction diet (SPRD). The 191 participants in this study were followed for approximately 4 years. In this study, CR-LIPE significantly decreased doubling of serum creatinine (relative risk, 0.53, 95% CI 0.33 to 0.86, p<0.01), all-cause mortality (relative risk, 0.5, 95% CI 0.2 to 1.12) and also delayed end-stage renal disease and renal replacement therapy when compared with SPRD. However, the CR-LIPE intervention was a multimodal dietary intervention that included carbohydrate restriction (35% of the energy intake) as one of the dietary modifications along with low-iron availability and polyphenol enrichment in the diet. Future study involving major adverse kidney endpoints is warranted to confirm if a ketogenic diet has beneficial impact on kidney disease.

Presumably because eGFR is less accurate at healthier function (eGFR >80 mL/min), some of these studies have shown that the beneficial effect of low carbohydrate diet is greater in those with lower starting baseline eGFR. For example, the study by Tirosch et al reported that the increase in eGFR was greater in those with CKD stage 3 (a 7.1-point; 10% eGFR increase from baseline) than the whole cohort (+5.3% increase from baseline) in the low carbohydrate arm. While other studies included a range of baseline eGFRs, the subset of patients with more significant kidney dysfunction (eGFR <60 mL/min) exhibited a slower decline in function, and no deterioration was evident in participants with normal baseline eGFR. Furthermore, caution is warranted when interpreting creatinine-derived eGFR measurements because any change in skeletal muscle mass during a nutritional study may affect the endogenous production of creatinine independent of actual changes in renal function. Hence, corroboration with cystatin-C measurements would strengthen these observations. The single-arm prospective 12 weeks study on individuals with relatively advanced diabetes nephropathy (eGFR <40 mL/min) reported statistically significant improvements in eGFR, serum creatinine, and cystatin C. Three additional retrospective observational studies reported improvements in kidney function in individuals following a low carbohydrate diet (online supplemental table 1). One of these studies reported improvement in eGFR and decrease in UACR at an average follow-up of 30 months while the other two studies reported eGFR improvement in individuals with reduced kidney function at baseline (eGFR <90 in one study and eGFR <70 in the other study).

In contrast, there were only two observational studies frequently cited when suggesting that a low carbohydrate diet is associated with adverse kidney outcomes. These studies did not focus on individuals adhering to a ketogenic diet or on those limiting their carbohydrate intake. For instance, Farhadnejad et al’s 2018 study, which was a population-based prospective analysis, investigated the association between different tertiles of low carbohydrate high protein (LCHP) scores and the incidence of CKD. Notably, none of the LCHP score tertiles in the study indicated a carbohydrate-restricted diet. Even in the tertile with the lowest LCHP score, carbohydrates contributed to 51.0% of the total energy, resembling the carbohydrate profile of a standard Western diet where 40%-60% of energy typically comes from carbohydrates. The other retrospective observational study by Li et al reported an association between elevated fasting ketone level with abnormal renal function in people with T2D who were admitted to the hospital, and who were not specifically eating a ketogenic diet. The association of ketones and renal function in this study is not relevant to dietary carbohydrate restriction in an ambulatory population.

Altogether, these clinical and observational studies show no harm from low or very low carbohydrate diets for people with diabetes in the setting of normal renal function, and a possible beneficial effect in the setting of moderately reduced renal function. The kidney function improvement observed in these studies may be an ancillary outcome associated with other improvements seen in these interventions including weight loss, glycemic control, or blood pressure improvement. Interestingly, Unwin et al reported no association between observed kidney function improvement with the magnitude of weight loss, improvement in blood pressure and HbA1c, while another study reported that the increase in eGFR was significantly associated with a decrease in fasting insulin and systolic blood pressure but not with the level of weight loss and protein intake in the intervention. In our previous study on patients with T2D following a very low carbohydrate intervention, there was a marginally significant increase in eGFR at 1 year. A post hoc analysis of these data revealed that a higher mean BHB at 1 year (β=5.04, p=0.005) was significantly associated with a greater increase in mean eGFR (unpublished data). Furthermore, in a subgroup analysis of 22 trial participants with an eGFR <60 mL/min/1.73m² at baseline who remained in the study for 2 years, the mean eGFR progressively increased from 51 mL/min/1.73m² to 60, 63, and 68 mL/min/1.73m² at 10 weeks, 1 year, and 2 years (unpublished data). Notably, the majority of the 22 participants reverted to stage 2 and no one progressed to stage 4 CKD. Evidently, a dose-dependent association exists between ketosis trajectory classes and the increase in total eGFR slope at 2 years. Participants with higher endogenous ketone concentration and longer duration of ketosis maintenance exhibited the greatest rise in the 2-year eGFR slope compared with those with lower endogenous ketone concentration and unsustainable ketosis maintenance. Hence, available evidence suggests that carbohydrate restriction and ketosis afford benefits to kidney function. It will be important to determine in future trials whether the improvement in kidney function translates to a sustained long-term reduction, or even reversal, in the progression of kidney disease.
Evidence from meta-analyses, systematic and narrative review

A recent review discussing the potential negative effect of purported ketogenic diets on kidney health focused on observational studies that compared low protein versus high protein diets that were not ketogenic or low carbohydrate diets, and raised concern about the association of albuminuria with high animal fat but only referred to observational studies that assessed high animal fat intake in the context of a Western diet, negating the relevance of the studies cited for concern.

In contrast, systematic reviews and meta-analyses that assessed pooled effects of RCTs reported beneficial effects of low-carbohydrate diets. The meta-analysis by Oyabu et al evaluated nine RCTs with 861 participants in the low carbohydrate arm and 826 participants in the control group. Despite a large variation in the proportion of carbohydrate intake from 4% to 45% in the low carbohydrate arm of the nine studies with a study duration ranging from 6 to 24 months, the review revealed that there was a significant increase in eGFR in the low carbohydrate group versus control group.

Another meta-analysis with 12 RCTs that only included patients with T2D reported no significant difference in the pooled eGFR and creatinine mean estimate between the lower carbohydrate diets (14%–45% of calories from carbohydrate) versus control diets over 5 weeks to 24 months. Similarly, another meta-analysis that included five RCTs with the low carbohydrate arm had carbohydrate intake ≤45%, and the studies ranging from 5 weeks to 24 months reported no difference in the pooled eGFR estimate between the control and low carbohydrate diets. The current evidence from systematic reviews and meta-analyses with a range of carbohydrate intake suggests that carbohydrate restriction is not associated with adverse effects on kidney function, or in some cases might be beneficial.

Evidence from genetically driven kidney disease

Individuals with autosomal dominant polycystic kidney disease (ADPKD) may benefit from calorie restriction or ketogenic diet. This chronic progressive condition is characterized by hyperproliferation, inflammation, fibrosis, and cyst growth, leading to deterioration of kidney function over time. mTOR is one of the main signaling pathways activated in ADPKD. A study of various polycystic kidney disease animal models showed that time-restricted feeding, administration of a ketogenic diet, or supplementation with exogenous BHB prevented kidney cyst disease progression by inhibiting cell proliferation, fibrosis, and cyst growth.

Furthermore, the mTOR activity was inhibited in these animal models suggesting that blunting the signaling pathway inhibits cell proliferation, growth, and fibrosis in ADPKD. In humans, a retrospective observational study of ADPKD patients who self-initiated ketosis either using ketogenic or time-restricted diets reported improvement in eGFR after 6 months. A pilot study on 24 patients with ADPKD demonstrated the feasibility of the ketogenic diet, reporting high adherence rates and improvements in blood pressure, eGFR, and kidney pain. In another exploratory RCT, 66 participants with ADPKD were randomized to ketogenic, water fasting, or control diets. The study confirmed the feasibility of the therapy in the ketogenic arm (KD) and revealed significant improvements in eGFR, including both creatinine and cystatin C-derived eGFR in the KD group but no improvements were observed in the water fasting and control diets. Additionally, there were no significant differences in UACR and blood pressure among the three diets.

Perspectives and future direction

There is a considerable body of research suggesting that a very low carbohydrate ketogenic diet is safe in individuals with moderately diminished kidney function, even in studies that had higher protein intake than what is recommended for kidney disease and diets that are not plant-based. The diet can be safely prescribed in patients with T2D for treating and remitting diabetes even if they have underlying stage 2 or 3 CKD or reduced kidney function. Beyond safety, mechanistic plausibility, preclinical data, and even some RCT studies suggest that carbohydrate-restricted diets may be beneficial in improving moderate kidney dysfunction and in reducing progression of CKD.

The preliminary proof of concept from small and short duration studies in humans and animals suggests a very low carbohydrate diet could be an effective dietary intervention for patients with CKD. Furthermore, there are predeveloped ketogenic nutritional options to consider when we plan a future trial to assess the impact of ketogenic diet on patients with CKD, such as the recently developed program for treating ADPKD known as Ren. Nu. This program is a plant-focused ketogenic medical nutrition therapy, designed to avoid renal stressors like oxalate, inorganic phosphate, and purines/uric acid. It includes a medical food formulation, KetoCitra, containing BHB with alkaline citrate which helps antagonize kidney stone formation. Based on the findings from these different studies and currently available ketogenic medical therapy specific for kidney disease, there is a need for future larger and longer follow-up randomized controlled clinical trials on very low carbohydrate diet, including nutritional ketosis in patients with CKD with or without T2D on kidney hard endpoints including major adverse kidney events (a composite event of death, persistent renal decline ≥25% decline in eGFR, and a new initiation of dialysis) and other kidney-related outcomes to firmly establish the long-term effectiveness. For example, a head-to-head comparison of the safety and efficacy of ketogenic nutritional therapy versus SGLT2i pharmacologic intervention (that involves the same mechanism of raising ketone levels) could be of high interest. Weight loss from the diet can improve filtration and albuminuria. Thus, including other surrogate endpoints like eGFR slope and microalbuminuria in these studies have the potential to elucidate the degree

to which weight loss and blood pressure improvement from the diet affects kidney function markers and also to explore if ketone levels independently have an impact on these markers and endpoints. Furthermore, these studies should also assess the diet’s overall safety in patients with T2D and CKD, specifically exploring its effect on net acid excretion, kidney stone formation, and maybe its beneficial effect on sodium retention hypertension. Finally, another important consideration in the clinical trial design for evaluating the efficacy of a very low carbohydrate diet in patients with CKD is understanding the diet’s additive role, especially how the diet interacts with currently available treatment drugs for patients with CKD including renin–angiotensin system blockade (angiotensin-converting enzyme inhibitor, ACEi and angiotensin receptor blockers, ARBs), SGLT2i, glucagon-like peptide-1 receptor agonists (GLP1-RA), and the non-steroidal mineralocorticoid receptor antagonists (finerenone).

Contributors SJA, JV and CGPR conceptualized the review topic and formulated the objectives; SJA conducted the comprehensive literature search, synthesized and interpreted the data from the collected literature; JSV drafted the original manuscript; JSV, TW, CGPR, and CV provided critical revisions and edits to the manuscript; ALM and GKS reviewed and edited the manuscript; All authors have read and agreed to the final version of the manuscript.

Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

Competing interests TW is an inventor on issued and pending patents filed by the University of California, Santa Barbara related to the topic of this article. TW is a founder and shareholder of Santa Barbara Nutrients, Inc., holds a managerial position, and has contributed to the development of the Ren.Nu ketogenic diet program and the medical food KetoCitra. TW received speaker fees from Otsuka, was a scientific advisor of Chinook Therapeutics, and serves as a science advisor for Simply Good Foods and Nutrishus Brands, and has authored books on ketogenic diets. SJA, CGPR, and GKS are employees and shareholders of Virta Health. ALM is a shareholder of Virta Health.

Patient consent for publication Not applicable.

Ethics approval Not applicable.

Provenance and peer review Not commissioned; externally peer reviewed.

Data availability statement No data are available.

Supplemental material This content has been supplied by the author(s). It has not been vetted by BMJ Publishing Group Limited (BMJ) and may not have been peer-reviewed. Any opinions or recommendations discussed are solely those of the author(s) and are not endorsed by BMJ. BMJ disclaims all liability and responsibility arising from any reliance placed on the content. Where the content includes any translated material, BMJ does not warrant the accuracy and reliability of the translations (including but not limited to local regulations, clinical guidelines, terminology, drug names and drug dosages), and is not responsible for any error and/or omissions arising from translation and adaptation or otherwise.

Open access This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/

ORCID iD Shaminie J Athinarayanan http://orcid.org/0000-0001-5427-6748

REFERENCES

Clinical care/Education/Nutrition

51 Milder JB, Liang LP, Patel M. Acute oxidative stress and systemic Nrf2 activation by the ketogenic diet. *Neurobiol Dis* 2010;40:238–44.
53 Jung J, Park WY, Kim YJ, et al. 3-Hydroxybutyrate ameliorates the progression of diabetic nephropathy. *Antioxidants (Basel)* 2022;11:381.
Supplementary Table 1. Summary of clinical and observational studies assessing the effect of low carbohydrate on kidney function and disease

<table>
<thead>
<tr>
<th>Study</th>
<th>Study Details</th>
<th>Details on Carbohydrate Restriction and Protein Intake</th>
<th>Kidney Function Findings</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Clinical Trials including post-hoc analyses</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Tay J et al., 2015</strong>&lt;sup&gt;113&lt;/sup&gt;</td>
<td>Randomized controlled trial (RCT) comparing a very low-carbohydrate, high-unsaturated fat/low-saturated fat diet (LC, carbohydrate &lt;50g/day; 14% energy) vs. a high-carbohydrate, low-fat diet (LF) on glycaemic control and CVD risk factors in T2D. Both diets were energy matched Follow-up duration 52 weeks Study included overweight and obese adults with type 2 diabetes (T2D) Baseline eGFR (mL/min/per 1.73m&lt;sup&gt;2&lt;/sup&gt;) was normal in both groups (LC, 96 and LF, 92)</td>
<td>Carbohydrate intake in LC stayed significantly lower than the LF group. Carbohydrate intake in the LC increased gradually from weeks 0-12 to weeks 37-52. Self-reported protein level and protein intake estimated from 24 hours urinary urea excretion was higher in LC (1.2g/kg/day) group versus LF (0.9g/kg/day).</td>
<td>No negative effect on kidney function Both intervention groups experienced non-significant decreases in eGFR (LC, -4%; LF, -2%) and albuminuria (LC, -42%; LF, -33%) with no difference between groups. The 2-4% decrease in eGFR is consistent with age-related change in T2D and at 52 weeks, the mean eGFR was still in normal range</td>
</tr>
<tr>
<td><strong>Tirosh A et al., 2013</strong>&lt;sup&gt;116&lt;/sup&gt;</td>
<td>RCT comparing 3 diets. Low fat (LF, restricted calorie with only 30% of the calories from fat), Mediterranean (M, moderate fat, restricted calorie diet) Low carbohydrate (LC, non-restricted calorie diet, with 20g carbohydrate per day during the first 2 month of induction phase and 120g carbohydrate per day during the maintenance phase) Follow-up duration 24 months Study included participants with BMI ≥</td>
<td>The LC intervention arm had significantly lower intake of carbohydrate and higher intake of protein than the other two intervention arms (LF and M) Only 8.3% of the LC arm participant had detectable urinary ketone at 24 mos (4.8% LF and 2.8% M participants had detectable urinary ketones)</td>
<td>Beneficial effect on kidney function All three intervention groups reported significant increase in eGFR from baseline but no significant difference between groups. LC, +5.3%; M, +5.2%; LF, +4.0% Among 23 participants who met microalbuminuria criteria at baseline, all three intervention</td>
</tr>
<tr>
<td>Study</td>
<td>Description</td>
<td>Findings</td>
<td></td>
</tr>
<tr>
<td>-------</td>
<td>-------------</td>
<td>----------</td>
<td></td>
</tr>
<tr>
<td>Brinkworth GD et al., 2010</td>
<td>RCT comparing energy-restricted very low carbohydrate diet (LC) and isocaloric conventional high carbohydrate diet (HC)</td>
<td>The LC group consumed significantly less carbohydrate and more protein than the HC arm. No negative effect on kidney function.</td>
<td></td>
</tr>
<tr>
<td>Friedman AN et al., 2012</td>
<td>RCT comparing low carbohydrate, high protein (LC) and energy restricted low fat (LF) groups.</td>
<td>The first 12 weeks, the LC arm limited carbohydrate intake &lt;20g per day. After 12 weeks, participants gradually increased carbohydrate intake at a rate of 5g/d per week. Beneficial effect on kidney function only at 3 and 12 months.</td>
<td></td>
</tr>
</tbody>
</table>

Baseline eGFR (mL/min/per 1.73m²) in all three intervention groups (LC, 71.1; M, 70.2 and LF, 70.3) arms had a non-significant decrease in albumin (LC, -37.0 mg/dL; M, -0.4 mg/dL and LF, -52.7 mg/dL). Subgroup analysis among those with moderate CKD stage III at baseline also reported significant increase in eGFR from baseline in the LC and M intervention arms. LC, +10.0%; M, +6.0%; LF, +5.4%

No significant changes in serum creatinine and eGFR from baseline to 1 year in both intervention arms. Both intervention arms had a significant decrease in urinary albumin excretion at 24 months.

Follow-up duration 24 months. LC reported significant decrease in serum creatinine and cystatin C at 3 months and relative increase in creatinine clearance at 3 months that lasted up to 12 months.
<table>
<thead>
<tr>
<th>Study</th>
<th>Design</th>
<th>Intervention</th>
<th>Key Findings</th>
<th>Additional Information</th>
</tr>
</thead>
<tbody>
<tr>
<td>Zainordin NA et al., 2021 115</td>
<td>RCT</td>
<td>Very low carbohydrate plus low protein diet (VLCBD) vs standard low protein/low salt (Control) diet groups</td>
<td>The VLCBD group had significantly lower carbohydrate count and higher daily intake of protein at 6 and 12 weeks compared to control.</td>
<td>No negative effect on kidney function</td>
</tr>
<tr>
<td></td>
<td>Follow-up duration 12 weeks</td>
<td></td>
<td></td>
<td>No significant decrease in eGFR and worsening of serum creatinine in both intervention group (with no difference between groups)</td>
</tr>
<tr>
<td></td>
<td>Study included individuals with T2D and stable CKD stages 2 or 3</td>
<td></td>
<td></td>
<td>There was a greater decrease in urine microalbumin in the VLCBD group (not significant from baseline) but no change in the control group.</td>
</tr>
<tr>
<td></td>
<td>Baseline eGFR (mL/min per 1.73m²) were 71.7 in VLCBD arm and 65.0 in control arm</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Facchini FS et al., 2003 117</td>
<td>RCT</td>
<td>Carbohydrate-restricted, low iron available, polyphenol enriched (CR-LIPE) diet vs standard protein restricted diet</td>
<td>The CR-LIPE restricted carbohydrate up to 30% and had a protein intake of 25 to 30% (2 to 2.4g/day) of the energy vs Control diet restricted protein up to 10% (0.8g/day) and had a carbohydrate intake of 65% of the energy</td>
<td>Beneficial effect on all-cause mortality and kidney endpoints</td>
</tr>
<tr>
<td></td>
<td>Mean follow-up duration 3.9 ± 1.8 years (approximately 4 years)</td>
<td></td>
<td></td>
<td>191 patients were enrolled, and 170 patients met the outcome or completed the last follow-up.</td>
</tr>
<tr>
<td></td>
<td>Study included individuals with T2D with different levels of renal failures including albuminuria</td>
<td></td>
<td></td>
<td>Doubling of serum creatinine reported in 19 patients on CR-LIPE (21%) and in 31 control patients (39%), relative risk (RR) 0.53 (95% CI 0.33-0.86, p&lt;0.01)</td>
</tr>
<tr>
<td></td>
<td>Baseline eGFR (mL/min) were 64.0 in CR-LIPE arm and 62.0 in control arm</td>
<td></td>
<td></td>
<td>All-cause mortality occurred in 8 patients on CR-LIPE (8.8%) and in 14 control subjects (17.7%), RR 0.5 (95% CI 0.2-1.12).</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Dialysis or renal replacement therapy occurred in 10 patients on CR-LIPE (11.0%) and in 17</td>
</tr>
<tr>
<td>Study</td>
<td>Design and Participants</td>
<td>Findings</td>
<td></td>
<td></td>
</tr>
<tr>
<td>-------</td>
<td>-------------------------</td>
<td>----------</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Bruci A et al., 2020&lt;sup&gt;119&lt;/sup&gt;</td>
<td>A single arm, prospective real-life follow-up study on individuals following a very low-calorie ketogenic diet (VLCKD)</td>
<td>No negative overall effect on kidney function but positive effect observed in individuals with diminished renal function at baseline.</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Friedman AN et al., 2013&lt;sup&gt;118&lt;/sup&gt;</td>
<td>A single arm, observational prospective follow-up on individuals following very low calorie ketogenic diet</td>
<td>Beneficial effect on kidney function</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Follow-up duration 3 months</td>
<td>No significant change in eGFR from baseline to 3 months in the whole cohort</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Study included individuals with obesity.</td>
<td>In the subgroup analysis after stratifying individuals into normal kidney function, NKF (eGFR≥90) and mild chronic kidney disease, MCKD (eGFR between 60 to 89) - no significant increase in eGFR reported in the NKF but the MCKD group had a significant 7.7% increase in eGFR at 3 months.</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Baseline eGFR (mL/min/1.73m²) was 94.5</td>
<td>27.7% of the participants in the MCKD group normalized their eGFR (eGFR≥90) at 3 months</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Ketosis was confirmed each week by measuring urinary ketone levels.</td>
<td>Carbohydrate intake was restricted to less than 50g/day</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>A significant 12% reduction in serum creatinine and cystatin C. A significant increase in eGFR</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>There was a non-significant 36% decrease in urine albumin excretion</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
### Observational studies

<table>
<thead>
<tr>
<th>Study</th>
<th>Description</th>
<th>Participants confirmed maintaining the low carbohydrate diet lifestyle</th>
<th>Beneficial effect on kidney function</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Unwin D et al., 2021</strong></td>
<td>A retrospective chart analysis of routine clinical data from a suburban GP practice where a low carbohydrate diet is prescribed routinely.</td>
<td>n=143 included in the analysis who persisted in the diet and with available data.</td>
<td>A significant increase in eGFR (2.8%) and decrease in urine albumin creatinine ratio. Serum creatinine also significantly decreased with 88% of individuals showing improvement in the creatinine levels.</td>
</tr>
<tr>
<td></td>
<td>Average follow-up duration 30 months</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Baseline eGFR (mL/min/per 1.73m$^2$) was 85.5</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

| **Mitchell NS et al., 2021**  | A retrospective cohort study of an outpatient ketogenic diet provider clinic. Included only patients who had at least two visits with the keto diet provider. | Recommended to restrict carbohydrate <20g and no restriction in protein and fat intake. | Beneficial effect observed in individuals with diminished renal function at baseline. |
|                              | Change in kidney function assessed at 1 year                                 | No details on adherence reported in the paper. |                                                                                                        |
|                              | n=2004 included in the final analysis, which includes                       |                                                                        |                                                                                                        |
|                              | n=823 with baseline eGFR ≥ 90 (E1)                                           |                                                                        |                                                                                                        |
|                              | n= 881 with baseline eGFR 60-89 (E2)                                         |                                                                        |                                                                                                        |
|                              | n=300 with baseline eGFR 30-59 (E3)                                         |                                                                        |                                                                                                        |
|                              | Baseline eGFR (mL/min/per 1.73m$^2$) of the overall cohort was 84.0        |                                                                        |                                                                                                        |

**Notes:**
- **BMJ Publishing Group Limited (BMJ) disclaims all liability and responsibility arising from any reliance placed on this supplemental material which has been supplied by the author(s).**
- **BMJ Open Diab Res Care**
- [doi: 10.1136/bmjdrc-2024-004101](https://doi.org/10.1136/bmjdrc-2024-004101)
loss, the eGFR improves 3 mL/min/1.73m\(^2\) and without any weight loss, the eGFR improves 1 mL/min/1.73m\(^2\).

For those in E3 category and with T2D, no changes in eGFR regardless of degree of weight loss.

**Wilmsen N et al., 2022**

A retrospective observational cohort study of participants who enrolled in the Reverse Diabetes 2Now program.

Participants with baseline eGFR<70 mL/min/1.73m\(^2\) were included in the final analysis (n=45)

Baseline median eGFR (mL/min/per 1.73m\(^2\)) of those included in the analysis and with available data is 62.0.

**Reverse Diabetes 2Now program aims to improve diet quality, sleep and physical activity.**

Participants were prescribed a restricted carb Mediterranean diet, rcMD.

It is not very clear how low carbohydrate was restricted in the intervention.

**Beneficial effect on kidney**

A significant increase in median eGFR from 62.0 at baseline to 69.0 at 6 months (an average increase of 8.1%). At 12 months (n=22 with available data), median eGFR (63.5) remains stable with no difference from baseline.

No changes in urinary albumin creatinine ratio (UACR) at 6 and 12 months. The median UACR was within normal range at baseline, 6 and 12 months.